Review ArticleReviews and Contemporary Updates

The Exercise Rehabilitation Paradox: Less May Be More?

Parham Parto, James H. O'Keefe and Carl J. Lavie
Ochsner Journal September 2016, 16 (3) 297-303;

Abstract

Background: Debatably, the most commonly prescribed lifestyle modification for cardiovascular health involves daily exercise training (ET) and physical activity. Exercise has numerous known health benefits on blood pressure, lipid profile, weight loss, and glucose metabolism. However, controversy exists regarding the link between excessive endurance ET and harmful cardiac effects.

Methods: We review the current literature and discuss the numerous known adverse effects of endurance ET on cardiac function.

Results: Excessive endurance ET may negatively affect cardiac anatomy, play a role in osteoarthritis and coronary artery disease development, and increase the risks of cardiac arrhythmia and sudden cardiac death.

Conclusion: More ET may not always be better when it comes to endurance ET, and optimal ET dosing regimens are clearly needed.

Keywords

INTRODUCTION

Daily exercise training (ET) and physical activity (PA) have long been praised as necessary components of lifestyle changes in the promotion of cardiovascular (CV) health. In association with a healthy diet, ET has known benefits such as lowering blood pressure, improving lipid profiles and glucose metabolism, and aiding weight loss.1,2 Studies have also reported the association of improved morbidity and mortality with increasing cardiorespiratory fitness levels and PA.3-6 The most recent evidence-based guidelines on PA, presented by the World Health Organization, recommend at least 150 min of moderate intensity aerobic ET or 75 min of vigorous intensity aerobic ET per week.7 Even with this evidence, most of the US and global populations (>50%) do not meet the PA levels recommended by these guidelines.3-6 On the opposite side of the spectrum, excessive ET and specifically excessive endurance ET (EEE), defined as ET >60-90 min in 1 session, occur in a much lower subset of the population (≤5%).3,8

In contrast to popular belief, more ET may not always be better, and current research has provided evidence of EEE being associated with deleterious cardiac effects. We discuss the evidence regarding the benefits of regular ET and PA on the heart and the adverse effects of EEE. We summarize structural changes that occur both acutely and with chronic exposure to ET, including the association with cardiac arrhythmia and the risk of sudden cardiac death (SCD). We also present data regarding the role that high intensity ET plays in the development of osteoarthritis (OA) and coronary artery disease (CAD) and the likely mortality benefits. Finally, we provide recommendations on the optimal ET dosing regimen and suggest screening tests for various populations.

CARDIAC FUNCTION AND STRUCTURE DURING EXERCISE TRAINING

Increases in cardiac output occur with ET in healthy adults from resting levels of approximately 5 L/min to >20-25 L/min with maximal effort and as high as approximately 40 L/min in elite athletes.9-11 Additionally, left ventricular stroke volume also increases with elevations in end-diastolic volume and myocardial contractility.9,12 Although in the acute setting variable increases in stroke volume are influenced by factors such as age, sex, and genetics, the adaptations seen in chronic ET occur irrespectively.9,13-16 Both left ventricular dilatation and hypertrophy have been reported with chronic aerobic ET, termed ET-induced cardiac remodeling. Similar adaptations have also been seen in the right atrium and right ventricle that collectively have positive effects on physiologic performance and lead to increased cardiac output with ET.9,15

With the sustained increases in cardiac work required by certain athletes and sports (such as running, swimming, rowing, and cycling), the structural adaptations that would otherwise be considered to hold poor cardiac prognosis have been described to be typical findings in “athlete's heart.”17-21 Unfortunately, some of the remodeling that occurs does not completely regress to normal levels, even after prolonged periods of deconditioning when the athlete has retired from sustained EEE.17,22 Marathon running is an example of a prolonged demand endurance sport; although of uncertain clinical significance, cardiac serologic markers associated with damage (troponin T, creatinine kinase-MB, B-type natriuretic peptide) are elevated in >30% and up to half of the athletes both during and after marathon running.17,23-27 Approximately one-third of marathon runners experience acute dilatations in cardiac chambers along with right ventricle and ventricular septum dysfunction that are restored at rest.3,8,17,28-30 However, the continuous exposure to strenuous ET and the resulting volume overload and strain cause dilatations within the cardiac chambers and may lead to patchy myocardial scarring within the right ventricle and right atrium in the long term.17-19,31-33 O'Keefe et al propose a potential pathogenesis of cardiomyopathy in endurance athletes (Figure 1).17

Figure 1.
Figure 1.

Proposed pathogenesis of cardiomyopathy in endurance athletes.17 BNP, B-type natriuretic peptide; CK-MB, creatine kinase-MB; LV, left ventricular; O2, oxygen; RA, right atrium; RV, right ventricular; SCD, sudden cardiac death. Reproduced with permission of Elsevier.

RUNNING AND OSTEOARTHRITIS

Susceptibility to OA has been linked to genetics, age, ethnicity, diet, obesity, and female sex.34,35 Weight loading and joint injury exacerbated by obesity and repetitive overuse can increase the progression and development of OA.34,35 The perception that, over time, running has negative effects on joints and joint function is common, and running has been proven to increase the risk of knee trauma and injuries, contributing to the development of OA.35,36 However, running also leads to weight loss, likely cartilage thickening, and prevention in cartilage proteoglycan loss, factors that offset the risk of OA development.36-42 Williams studied 74,752 runners and 14,625 walkers during a 5-7 year period and found that compared to those who ran less than 1.8 metabolic equivalent of task (MET)–hours per day (MET-h/d), those who ran 1.8-3.6 MET-h/d had 18% and 35% reductions in the risk of OA and hip replacement, respectively.36,42 The risk reductions seen by exceeding 1.8 MET-h/d did not differ significantly. More important, body mass index (BMI) was strongly associated with OA (5.0% increase for every kg/m2, P=2×10−8). Exercises other than running increased the risk of OA by 2.4% (P=0.009) for each MET-h/d, independent of BMI. As such, one can reasonably assume that the significant risk reduction for OA seen with running may largely be a result of the association with lower BMI.36

Kujala et al evaluated the risk of OA in 2,049 ex-professional athletes during a 21-year period who were involved in endurance sports (long-distance running, cross-country skiing), mixed sports (soccer, ice hockey, basketball, track and field), and power sports (boxing, wrestling, weight-lifting, and throwing sports).43 The risk of OA was increased in all forms of competitive sports: in endurance athletes (odds ratio [OR] 1.73, 95% confidence interval [CI] 0.99-3.01, P=0.063), in mixed sports athletes (OR 1.90, 95% CI 1.24-2.92, P=0.003), and in power sports athletes (OR 2.17, 95% CI 1.41-3.32, P=0.0003). However, the authors noted that the endurance athletes seemed to require hospitalization for OA at older ages compared to the other groups.35,43

Marti et al retrospectively compared former long-distance runners to bobsleigh riders and healthy untrained controls and found that subchondral sclerosis, osteophyte formation, and joint space narrowing were significantly increased in the runners compared to the other groups.44 Additionally, running pace was a stronger predictor of subsequent degenerative hip disease than running mileage, suggesting that long-term, high-intensity running, along with high-mileage running, may be a potential risk factor for hip OA.44

SUDDEN CARDIAC DEATH

Cardiac arrhythmia and SCD have long been associated with endurance sports. Partly driven by awareness and promotion of the beneficial effects of regular ET, the number of Americans taking part in marathons and half-marathons has increased as much as 25 times in the past 40 years (Figure 2).1,3,17,25,28,45 Kim et al reported incidence rates of cardiac arrest and SCD during marathon and half marathon races as 1 in 184,000 and 1 in 259,000, respectively.25 Although this study may have underestimated actual rates by including half-marathon runners and only including events during the marathon itself and not during the postrace period, the fatalities nevertheless remain relatively uncommon and much rarer than the incidence seen in collegiate athletes (approximately 1 in 40,000 per year for all athletes).3,24,46,47 Interestingly, the final 1 mile of marathon courses has been shown to account for half of SCDs that occur during the race.17,25,26

Figure 2.
Figure 2.

Marathon running trends in the United States from 1976-2011.1 Copyright Missouri Medicine. Used with permission.

EXERCISE TRAINING AND CARDIAC ARRHYTHMIA

When considering the changes in cardiac structure and the scarring that occur with long-term EET, one can reasonably presume that EEE promotes an arrhythmogenic environment, especially in the pliable chambers of the heart (the atria and the right ventricle).17,48,49 Approximately a 5-fold increased risk of atrial fibrillation (AF) in athletes (marathon runners, ultramarathon runners, professional cyclists) has been documented in the literature.17,19,48,50-53 Although speculative, some of the proposed mechanisms underlying AF development in chronic EEE are increases in atrial size, vagal tone, sympathetic tone, bradycardia, catecholamine fluxes, right ventricle cardiomyopathy, and atrial wall fibrosis and stretching.3,17,54 Indeed, left atrial enlargement has been found in up to 20% of competitive athletes, possibly contributing to AF development.17,54 Drca et al evaluated 44,410 men and reported an increased risk (risk ratio [RR] 1.19, 95% CI 1.05-1.36) of AF development later in life in 30-year-olds who had participated in intense ET for >5 hours per week and a decreased risk (RR 0.87, 95% CI 0.77-0.97) in those who participated in moderate ET (walking or bicycling).55 The Cardiovascular Health Study reported a similar finding in adults >65 years.56 ET intensity and lifetime quantity both showed a U-shaped relationship with AF (P=0.02), with light to moderate ET significantly associated with lower AF incidence and high-intensity ET significantly associated with increased risk of AF.3,56 Calvo et al evaluated the impact of PA quantity in patients with lone AF and found a correlation between lone AF and vigorous endurance training (cumulative ≥2,000 hours) (Figure 3).57

Figure 3.
Figure 3.

The percentage (95% confidence interval) of participants with lone atrial fibrillation according to accumulated high-intensity physical exercise. Reproduced with permission from Calvo et al.57

Although electrocardiographic abnormalities in athletes are usually considered benign, complex findings may suggest a need for further investigation. A study of 46 high-level endurance athletes with ventricular arrhythmia reported a predominance for left bundle branch morphology with right ventricle arrhythmogenic involvement in 59%, and this abnormality was suggested in another 30%.58 Even in the absence of familial arrhythmogenic right ventricle cardiomyopathy, ventricular arrhythmia in high-level athletes is frequently found to originate from mild right ventricle dysfunction, and EEE may possibly act as a trigger.32

PLAQUE BURDEN AND CORONARY ARTERY DISEASE

One of the potential benefits of ET, based on years of epidemiologic data, is the contribution to the reduction of risk factors for cardiovascular disease (CVD).9,59-62 Despite popular belief and the presumption that running protects against coronary artery plaque formation, recent data suggest that long-distance runners are at increased risk of higher levels of atherosclerosis and CAD than those who engage in less-intense ET.1,3,8 Möhlenkamp et al reported increased coronary event rates with elevated coronary artery calcium scores (CACs) (21% with CAC ≥400, P=0.002) and prevalent myocardial fibrosis in marathon runners compared to risk factor–matched controls.3,63 A 2014 study evaluating long-term marathon running (completing at least 1 marathon per year for 25 consecutive years) found increased total plaque, calcified plaque, and noncalcified plaque volume in the group of marathon runners compared to the sedentary control group (Figure 4).1,3 One explanation for these findings may be because of vascular function, oxidative stress, and the production of atherogenic particles induced with intense long-term repetitive ET.1,64 In a 2011 randomized clinical trial, short ET duration (30 min) was associated with favorable antioxidant and vascular effects, while long (30-60 min) ET duration was associated with adverse effects on vascular function.64

Figure 4.
Figure 4.

Total plaque burden in marathon runners vs control subjects shows that runners had significantly higher total coronary plaque volume, noncalcified plaque volume, and calcified plaque volume.1 Copyright Missouri Medicine. Used with permission.

MORBIDITY AND MORTALITY

The Copenhagen City Heart study reported a remarkable 44% lower risk of mortality for joggers compared to nonjoggers, with an age-adjusted increase in survival of approximately 6 years in both men and women.29,65 Interestingly, the authors discovered U-shaped curves for mortality with respect to speed, frequency, and quantity of jogging, suggesting that the optimal benefit from jogging is seen in those who jog at a slow to moderate pace, between 1.0-2.5 hours per week 2-3 times per week.29,65 Jogging at higher intensity and quantity appeared to actually diminish the remarkable gains in longevity that were obtained by moderate levels of jogging.29,65 Lee et al evaluated 55,137 adults during a 15-year period and found that compared to nonrunners, runners had lower adjusted risks of all-cause (30%) and CVD (45%) mortalities, in addition to a 3-year benefit in life expectancy and 4.1 years in CV life.66 Even running at slow speeds (<6 miles/hour) for short periods of time (5-10 min/day) had markedly improved mortality benefits (Figure 5).66 Prior investigations support higher mortality benefits in individuals achieving MET levels >10.42,67-69 Interestingly, persistent runners appear to get full mortality benefits compared to those who were running but stopped and those who were not runners. The former runners and nonrunners achieved only half the benefit.44,66 Williams and Thompson reported mortality benefits in patients with prior myocardial infarctions (MIs): a CVD mortality risk-reduction average of 15% per every MET-h/d up to 7.2 MET-h/d.70 Beyond 7.2 MET-h/d, a significant risk increase was noted, suggesting that the mortality benefits for patients with known heart disease and prior MIs have a benefit threshold of approximately 7 MET-h/d, the rough equivalent of 30 miles per week of running and 46 miles per week of walking.70

Figure 5.
Figure 5.

Hazard ratios of all-cause and cardiovascular disease (CVD) mortality by change in running behaviors. Model 1 adjusted for baseline age (years), sex, examination year, and interval between baseline and last examinations. Model 2 adjusted for model 1 in addition to baseline smoking (never, former, or current), alcohol consumption (heavy drinker or not), other physical activities except running (0, 1 to 499, or ≥500 metabolic equivalent of task–minutes per week), and parental CVD. The number of participants (deaths) in the groups of remained nonrunners, became nonrunners, became runners, and remained runners were 13,522 (1,013), 2,847 (141), 1,578 (131), and 2,700 (113) for all-cause mortality and 12,885 (376), 2,753 (47), 1,485 (38), and 2,616 (29) for cardiovascular mortality, respectively. The bars indicate 95% confidence interval, and hazard ratios are shown next to the bars.66 Reproduced with permission of Elsevier.

OPTIMAL DOSING AND RECOMMENDATIONS

Regular aerobic ET and a heart-healthy diet are recommended often as lifestyle modifications. However, ET regimens should be prescribed at proper dosages and intervals, just as medications. As mentioned earlier, less than half of American adults meet the minimum ET requirements set forth by the most recent Physical Activity Guidelines for Americans by the US Department of Health and Human Services; on the opposite end of the spectrum, a small population (approximately 5%) may be overdosing with too much ET.3-6,8,71 The data suggest that even at levels below the recommendation (150 min/week of moderate or 75 min/week of vigorous aerobic PA) significant health benefits are seen. 65,66,72-74 In a 2014 study, Wen et al found that a 15-min walk produces the same benefits as a 5-min run, and a 105-min walk produces the same benefits as a 25-min run.75 The maximal benefits of running appear to occur at low levels and at approximately 40 min/day or less.42,65,66,72-75 Although marathons and triathlons are associated with some risk, that risk is not high, and athletes should be not discouraged from participating.42 Of note, the typical sports that most individuals are involved in during adolescence, and some during adulthood (ie, football, soccer, basketball), do not involve sustained intense aerobic PA, the main pattern of concern for cardiac overuse injury.28

Specific ET guidelines and recommendations do not exist for patients >50 years with known CAD and CVD risk factors or prior MIs. Some researchers recommend CAC scanning, exercise stress testing, low-dose aspirin therapy, and statin therapy for this population.42,76 Individuals with these risk factors who are considering initiating EEE or vigorous PA may benefit from some of the same recommendations. No screening protocol exists for athletes partaking in EEE. However, an acceptable strategy may involve posttraining measurement of cardiac biomarkers to monitor cardiac muscle injury, aortic pulse wave velocity to evaluate for arterial stiffness, and periodic echocardiography or cardiac magnetic resonance imaging to help further risk-stratify patients with structural remodeling and myocardial scarring and identify proarrhythmic substrate.30,77

CONCLUSION

The benefits of regular ET and PA along with a healthy diet and lifestyle are clear. Although the motivation to exercise varies for each individual, the current PA guidelines provide reasonable recommendations for the general population. Educating athletes who choose to participate in EEE about the health risks is important, although the risks are relatively low. Furthermore, the overall benefits of running far outweigh the risks for most. Further studies are needed to develop consensus-based guidelines regarding athletics in special populations.

This article meets the Accreditation Council for Graduate Medical Education and the American Board of Medical Specialties Maintenance of Certification competencies for Patient Care and Medical Knowledge.

ACKNOWLEDGMENTS

The authors have no financial or proprietary interest in the subject matter of this article.

REFERENCES

  1. ↵
    1. Schwartz RS,
    2. Kraus SM,
    3. Schwartz JG,
    4. et al.
    Increased coronary artery plaque volume among male marathon runners. Mo Med. 2014 Mar-Apr; 111 2: 85- 90.
    OpenUrl
  2. ↵
    1. Lippi G,
    2. Schena F,
    3. Salvagno GL,
    4. Montagnana M,
    5. Ballestrieri F,
    6. Guidi GC.
    Comparison of the lipid profile and lipoprotein(a) between sedentary and highly trained subjects. Clin Chem Lab Med. 2006; 44 3: 322- 326. pmid:16519606
    OpenUrlCrossRefPubMed
  3. ↵
    1. Lavie CJ,
    2. O'Keefe JH,
    3. Sallis RE.
    Exercise and the heart--the harm of too little and too much. Curr Sports Med Rep. 2015 Mar-Apr; 14 2: 104- 109. doi: 10.1249/JSR.0000000000000134. pmid:25757005
    OpenUrlCrossRefPubMed
    1. Franklin BA,
    2. Lavie CJ,
    3. Squires RW,
    4. Milani RV.
    Exercise-based cardiac rehabilitation and improvements in cardiorespiratory fitness: implications regarding patient benefit. Mayo Clin Proc. 2013 5; 88 5: 431- 437. doi: 10.1016/j.mayocp.2013.03.009. pmid:23639495
    OpenUrlCrossRefPubMed
    1. Swift DL,
    2. Lavie CJ,
    3. Johannsen NM,
    4. et al.
    Physical activity, cardiorespiratory fitness, and exercise training in primary and secondary coronary prevention. Circ J. 2013; 77 2: 281- 292. pmid:23328449
    OpenUrlCrossRefPubMed
  6. ↵
    1. Vuori IM,
    2. Lavie CJ,
    3. Blair SN.
    Physical activity promotion in the health care system. Mayo Clin Proc. 2013 12; 88 12: 1446- 1461. doi: 10.1016/j.mayocp.2013.08.020. pmid:24290119
    OpenUrlCrossRefPubMed
  7. ↵
    Global Recommendations on Physical Activity for Health World Health Organization . http://apps.who.int/iris/bitstream/10665/44399/1/9789241599979_eng.pdf. Accessed July 14, 2016.
  8. ↵
    1. McCullough P,
    2. Lavie C.
    Coronary artery plaque and cardiotoxicity as a result of extreme endurance exercise. Mol Med. 2014; 111: 85- 90.
    OpenUrl
  9. ↵
    1. Lavie CJ,
    2. Arena R,
    3. Swift DL,
    4. et al.
    Exercise and the cardiovascular system: clinical science and cardiovascular outcomes. Circ Res. 2015 7 3; 117 2: 207- 219. doi: 10.1161/CIRCRESAHA.117.305205. pmid:26139859
    OpenUrlAbstract/FREE Full Text
    1. Rivera-Brown AM,
    2. Frontera WR.
    Principles of exercise physiology: responses to acute exercise and long-term adaptations to training. PM R. 2012 11; 4 11: 797- 804. doi: 10.1016/j.pmrj.2012.10.007. pmid:23174541
    OpenUrlCrossRefPubMed
  11. ↵
    1. Arena R,
    2. Myers J,
    3. Guazzi M.
    The clinical significance of aerobic exercise testing and prescription: from apparently healthy to confirmed cardiovascular disease. Am J Lifestyle Med. 2008 Nov-Dec; 2 6: 519- 536. doi: 10.1177/1559827608323210.
    OpenUrlCrossRef
  12. ↵
    1. Froelicher V,
    2. Myers J
    1. Froelicher V,
    2. Myers J.
    Basic exercise physiology. : Froelicher V, Myers J Exercise and the Heart. 5th ed. Philadelphia, PA: W.B. Saunders Co.; 2006: 1- 10.
  13. ↵
    1. Seals DR,
    2. Hagberg JM,
    3. Spina RJ,
    4. Rogers MA,
    5. Schechtman KB,
    6. Ehsani AA.
    Enhanced left ventricular performance in endurance trained older men. Circulation. 1994 1; 89 1: 198- 205. pmid:8281647
    OpenUrlAbstract/FREE Full Text
    1. Baggish AL,
    2. Yared K,
    3. Wang F,
    4. et al.
    The impact of endurance exercise training on left ventricular systolic mechanics. Am J Physiol Heart Circ Physiol. 2008 9; 295 3: H1109- H1116. doi: 10.1152/ajpheart.00395.2008. pmid:18621855
    OpenUrlCrossRefPubMed
  15. ↵
    1. Weiner RB,
    2. Baggish AL.
    Exercise-induced cardiac remodeling. Prog Cardiovasc Dis. 2012 Mar-Apr; 54 5: 380- 386. doi: 10.1016/j.pcad.2012.01.006. pmid:22386288
    OpenUrlCrossRefPubMed
  16. ↵
    1. Arbab-Zadeh A,
    2. Perhonen M,
    3. Howden E,
    4. et al.
    Cardiac remodeling in response to 1 year of intensive endurance training. Circulation. 2014 12 9; 130 24: 2152- 2161. doi: 10.1161/CIRCULATIONAHA.114.010775. pmid:25281664
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. O'Keefe JH,
    2. Patil HR,
    3. Lavie CJ,
    4. Magalski A,
    5. Vogel RA,
    6. McCullough PA.
    Potential adverse cardiovascular effects from excessive endurance exercise. Mayo Clin Proc. 2012 6; 87 6: 587- 595. doi: 10.1016/j.mayocp.2012.04.005. pmid:22677079
    OpenUrlCrossRefPubMed
    1. Pluim BM,
    2. Zwinderman AH,
    3. van der Laarse A,
    4. van der Wall EE.
    The athlete's heart. A meta-analysis of cardiac structure and function. Circulation. 2000 1 25; 101 3: 336- 344. pmid:10645932
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Maron BJ,
    2. Pelliccia A.
    The heart of trained athletes: cardiac remodeling and the risks of sports, including sudden death. Circulation. 2006 10 10; 114 15: 1633- 1644. pmid:17030703
    OpenUrlFREE Full Text
    1. Spirito P,
    2. Pelliccia A,
    3. Proschan MA,
    4. et al.
    Morphology of the “athlete's heart” assessed by echocardiography in 947 elite athletes representing 27 sports. Am J Cardiol. 1994 10 15; 74 8: 802- 806. pmid:7942554
    OpenUrlCrossRefPubMed
  21. ↵
    1. Maron BJ.
    Hypertrophic cardiomyopathy and other causes of sudden cardiac death in young competitive athletes, with considerations for preparticipation screening and criteria for disqualification. Cardiol Clin. 2007 8; 25 3: 399- 414. pmid:17961794
    OpenUrlCrossRefPubMed
  22. ↵
    1. Pelliccia A,
    2. Maron BJ,
    3. De Luca R,
    4. Di Paolo FM,
    5. Spataro A,
    6. Culasso F.
    Remodeling of left ventricular hypertrophy in elite athletes after long-term deconditioning. Circulation. 2002 2 26; 105 8: 944- 949. pmid:11864923
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Lee D,
    2. Pate RR,
    3. Lavie CJ,
    4. Blair SN.
    Running and all-cause mortality risk - is more better. Med Sci Sports Exerc. 2012; 44: 924.
    OpenUrl
  24. ↵
    1. Redelmeier DA,
    2. Greenwald JA.
    Competing risks of mortality with marathons: retrospective analysis. BMJ. 2007 12 22; 335 7633: 1275- 1277. pmid:18156224
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Kim JH,
    2. Malhotra R,
    3. Chiampas G,
    4. et al.
    Race Associated Cardiac Arrest Event Registry (RACER) Study Group. Cardiac arrest during long-distance running races. N Engl J Med. 2012 1 12; 366 2: 130- 140. doi: 10.1056/NEJMoa1106468. pmid:22236223
    OpenUrlCrossRefPubMed
  26. ↵
    1. Sheppard MN.
    The fittest person in the morgue? Histopathology. 2012 2; 60 3: 381- 396. doi: 10.1111/j.1365-2559.2011.03852.x. pmid:21668469
    OpenUrlCrossRefPubMed
  27. ↵
    1. Harris KM,
    2. Henry JT,
    3. Rohman E,
    4. Haas TS,
    5. Maron BJ.
    Sudden death during the triathlon. JAMA. 2010 4 7; 303 13: 1255- 1257. doi: 10.1001/jama.2010.368. pmid:20371783
    OpenUrlCrossRefPubMed
  28. ↵
    1. O'Keefe JH,
    2. Franklin B,
    3. Lavie CJ.
    Exercising for health and longevity vs peak performance: different regimens for different goals. Mayo Clin Proc. 2014 9; 89 9: 1171- 1175. doi: 10.1016/j.mayocp.2014.07.007. pmid:25128073
    OpenUrlCrossRefPubMed
  29. ↵
    1. O'Keefe JH,
    2. Schnohr P,
    3. Lavie CJ.
    The dose of running that best confers longevity. Heart. 2013 4; 99 8: 588- 590. doi: 10.1136/heartjnl-2013-303683. pmid:23512971
    OpenUrlFREE Full Text
  30. ↵
    1. Patil HR,
    2. O'Keefe JH,
    3. Lavie CJ,
    4. Magalski A,
    5. Vogel RA,
    6. McCullough PA.
    Cardiovascular damage resulting from chronic excessive endurance exercise. Mo Med. 2012 Jul-Aug; 109 4: 312- 321. pmid:22953596
    OpenUrlPubMed
  31. ↵
    1. Maron BJ,
    2. Pelliccia A,
    3. Spirito P.
    Cardiac disease in young trained athletes. Insights into methods for distinguishing athlete's heart from structural heart disease, with particular emphasis on hypertrophic cardiomyopathy. Circulation. 1995 3; 91 5: 1596- 1601. pmid:7867202
    OpenUrlFREE Full Text
  32. ↵
    1. Ector J,
    2. Ganame J,
    3. van der Merwe N,
    4. et al.
    Reduced right ventricular ejection fraction in endurance athletes presenting with ventricular arrhythmias: a quantitative angiographic assessment. Eur Heart J. 2007 2; 28 3: 345- 353. pmid:17242015
    OpenUrlCrossRefPubMed
  33. ↵
    1. Nassenstein K,
    2. Breuckmann F,
    3. Lehmann N,
    4. et al.
    Left ventricular volumes and mass in marathon runners and their association with cardiovascular risk factors. Int J Cardiovasc Imaging. 2009 1; 25 1: 71- 79. doi: 10.1007/s10554-008-9337-x. pmid:18677576
    OpenUrlCrossRefPubMed
  34. ↵
    1. Felson DT.
    An update on the pathogenesis and epidemiology of osteoarthritis. Radiol Clin North Am. 2004 1; 42 1: 1- 9. pmid:15049520
    OpenUrlCrossRefPubMed
  35. ↵
    1. Hunter DJ,
    2. Eckstein F.
    Exercise and osteoarthritis. J Anat. 2009 2; 214 2: 197- 207. doi: 10.1111/j.1469-7580.2008.01013.x. pmid:19207981
    OpenUrlCrossRefPubMed
  36. ↵
    1. Williams PT.
    Effects of running and walking on osteoarthritis and hip replacement risk. Med Sci Sports Exerc. 2013 7; 45 7: 1292- 1297. doi: 10.1249/MSS.0b013e3182885f26. pmid:23377837
    OpenUrlCrossRefPubMed
    1. Cooper C,
    2. Snow S,
    3. McAlindon TE,
    4. et al.
    Risk factors for the incidence and progression of radiographic knee osteoarthritis. Arthritis Rheum. 2000 5; 43 5: 995- 1000. pmid:10817551
    OpenUrlCrossRefPubMed
    1. Jones G,
    2. Ding C,
    3. Glisson M,
    4. Hynes K,
    5. Ma D,
    6. Cicuttini F.
    Knee articular cartilage development in children: a longitudinal study of the effect of sex, growth, body composition, and physical activity. Pediatr Res. 2003 8; 54 2: 230- 236. pmid:12736391
    OpenUrlCrossRefPubMed
    1. Jones G,
    2. Glisson M,
    3. Hynes K,
    4. Cicuttini F.
    Sex and site differences in cartilage development: a possible explanation for variations in knee osteoarthritis in later life. Arthritis Rheum. 2000 11; 43 11: 2543- 2549. pmid:11083279
    OpenUrlCrossRefPubMed
    1. Roos EM,
    2. Dahlberg L.
    Positive effects of moderate exercise on glycosaminoglycan content in knee cartilage: a four-month, randomized, controlled trial in patients at risk of osteoarthritis. Arthritis Rheum. 2005 11; 52 11: 3507- 3514. pmid:16258919
    OpenUrlCrossRefPubMed
    1. Tiderius CJ,
    2. Svensson J,
    3. Leander P,
    4. Ola T,
    5. Dahlberg L.
    dGEMRIC (delayed gadolinium-enhanced MRI of cartilage) indicates adaptive capacity of human knee cartilage. Magn Reson Med. 2004 2; 51 2: 286- 290. pmid:14755653
    OpenUrlCrossRefPubMed
  42. ↵
    1. Lavie CJ,
    2. Lee DC,
    3. Sui X,
    4. et al.
    Effects of running on chronic diseases and cardiovascular and all-cause mortality. Mayo Clin Proc. 2015 11; 90 11: 1541- 1552. doi: 10.1016/j.mayocp.2015.08.001. pmid:26362561
    OpenUrlCrossRefPubMed
  43. ↵
    1. Kujala UM,
    2. Kaprio J,
    3. Sarna S.
    Osteoarthritis of weight bearing joints of lower limbs in former élite male athletes. BMJ. 1994 1 22; 308 6923: 231- 234. pmid:8111258
    OpenUrlAbstract/FREE Full Text
  44. ↵
    1. Marti B,
    2. Knobloch M,
    3. Tschopp A,
    4. Jucker A,
    5. Howald H.
    Is excessive running predictive of degenerative hip disease? Controlled study of former elite athletes. BMJ. 1989 7 8; 299 6691: 91- 93. pmid:2504343
    OpenUrlAbstract/FREE Full Text
  45. ↵
    1. O'Keefe JH,
    2. Lavie CJ,
    3. Guazzi M.
    Part 1: potential dangers of extreme endurance exercise: how much is too much? Part 2: screening of school-age athletes. Prog Cardiovasc Dis. 2015 Jan-Feb; 57 4: 396- 405. doi: 10.1016/j.pcad.2014.11.004. pmid:25460846
    OpenUrlCrossRefPubMed
  46. ↵
    1. Roberts WO,
    2. Roberts DM,
    3. Lunos S.
    Marathon related cardiac arrest risk differences in men and women. Br J Sports Med. 2013 2; 47 3: 168- 171. doi: 10.1136/bjsports-2012-091119. pmid:22736205
    OpenUrlAbstract/FREE Full Text
  47. ↵
    1. Harmon KG,
    2. Asif IM,
    3. Klossner D,
    4. Drezner JA.
    Incidence of sudden cardiac death in National Collegiate Athletic Association athletes. Circulation. 2011 4 19; 123 15: 1594- 1600. doi: 10.1161/CIRCULATIONAHA.110.004622. pmid:21464047
    OpenUrlAbstract/FREE Full Text
  48. ↵
    1. Breuckmann F,
    2. Möhlenkamp S,
    3. Nassenstein K,
    4. et al.
    Myocardial late gadolinium enhancement: prevalence, pattern, and prognostic relevance in marathon runners. Radiology. 2009 4; 251 1: 50- 57. doi: 10.1148/radiol.2511081118. pmid:19332846
    OpenUrlCrossRefPubMed
  49. ↵
    1. Goel R,
    2. Majeed F,
    3. Vogel R,
    4. et al.
    Exercise-induced hypertension, endothelial dysfunction, and coronary artery disease in a marathon runner. Am J Cardiol. 2007 3 1; 99 5: 743- 744. pmid:17317385
    OpenUrlCrossRefPubMed
  50. ↵
    1. Neilan TG,
    2. Januzzi JL,
    3. Lee-Lewandrowski E,
    4. et al.
    Myocardial injury and ventricular dysfunction related to training levels among nonelite participants in the Boston marathon. Circulation. 2006 11 28; 114 22: 2325- 2333. pmid:17101848
    OpenUrlAbstract/FREE Full Text
    1. Vlachopoulos C,
    2. Aznaouridis K,
    3. Stefanadis C.
    Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010 3 30; 55 13: 1318- 1327. doi: 10.1016/j.jacc.2009.10.061. pmid:20338492
    OpenUrlFREE Full Text
    1. Elosua R,
    2. Arquer A,
    3. Mont L,
    4. et al.
    Sport practice and the risk of lone atrial fibrillation: a case-control study. Int J Cardiol. 2006 4 14; 108 3: 332- 337. pmid:15963583
    OpenUrlCrossRefPubMed
  53. ↵
    1. Aizer A,
    2. Gaziano JM,
    3. Cook NR,
    4. Manson JE,
    5. Buring JE,
    6. Albert CM.
    Relation of vigorous exercise to risk of atrial fibrillation. Am J Cardiol. 2009 6 1; 103 11: 1572- 1577. doi: 10.1016/j.amjcard.2009.01.374. pmid:19463518
    OpenUrlCrossRefPubMed
  54. ↵
    1. Mont L,
    2. Sambola A,
    3. Brugada J,
    4. et al.
    Long-lasting sport practice and lone atrial fibrillation. Eur Heart J. 2002 3; 23 6: 477- 482. pmid:11863350
    OpenUrlCrossRefPubMed
  55. ↵
    1. Drca N,
    2. Wolk A,
    3. Jensen-Urstad M,
    4. Larsson SC.
    Atrial fibrillation is associated with different levels of physical activity levels at different ages in men. Heart. 2014 7; 100 13: 1037- 1042. doi: 10.1136/heartjnl-2013-305304. pmid:24829373
    OpenUrlAbstract/FREE Full Text
  56. ↵
    1. Mozaffarian D,
    2. Furberg CD,
    3. Psaty BM,
    4. Siscovick D.
    Physical activity and incidence of atrial fibrillation in older adults: the cardiovascular health study. Circulation. 2008 8 19; 118 8: 800- 807. doi: 10.1161/CIRCULATIONAHA.108.785626. pmid:18678768
    OpenUrlAbstract/FREE Full Text
  57. ↵
    1. Calvo N,
    2. Ramos P,
    3. Montserrat S,
    4. et al.
    Emerging risk factors and the dose-response relationship between physical activity and lone atrial fibrillation: a prospective case-control study. Europace. 2016 1; 18 1: 57- 63. doi: 10.1093/europace/euv216. pmid:26333377
    OpenUrlCrossRefPubMed
  58. ↵
    1. Heidbüchel H,
    2. Hoogsteen J,
    3. Fagard R,
    4. et al.
    High prevalence of right ventricular involvement in endurance athletes with ventricular arrhythmias. Role of an electrophysiologic study in risk stratification. Eur Heart J. 2003 8; 24 16: 1473- 1480. pmid:12919770
    OpenUrlCrossRefPubMed
  59. ↵
    1. Hu G,
    2. Barengo NC,
    3. Tuomilehto J,
    4. Lakka TA,
    5. Nissinen A,
    6. Jousilahti P.
    Relationship of physical activity and body mass index to the risk of hypertension: a prospective study in Finland. Hypertension. 2004 1; 43 1: 25- 30. pmid:14656958
    OpenUrlCrossRefPubMed
    1. Lahti-Koski M,
    2. Pietinen P,
    3. Heliövaara M,
    4. Vartiainen E.
    Associations of body mass index and obesity with physical activity, food choices, alcohol intake, and smoking in the 1982-1997 FINRISK Studies. Am J Clin Nutr. 2002 5; 75 5: 809- 817. pmid:11976153
    OpenUrlAbstract/FREE Full Text
    1. Kriska AM,
    2. Saremi A,
    3. Hanson RL,
    4. et al.
    Physical activity, obesity, and the incidence of type 2 diabetes in a high-risk population. Am J Epidemiol. 2003 10 1; 158 7: 669- 675. pmid:14507603
    OpenUrlCrossRefPubMed
  62. ↵
    1. Rennie KL,
    2. McCarthy N,
    3. Yazdgerdi S,
    4. Marmot M,
    5. Brunner E.
    Association of the metabolic syndrome with both vigorous and moderate physical activity. Int J Epidemiol. 2003 8; 32 4: 600- 606. pmid:12913036
    OpenUrlCrossRefPubMed
  63. ↵
    1. Möhlenkamp S,
    2. Leineweber K,
    3. Lehmann N,
    4. et al.
    Coronary atherosclerosis burden, but not transient troponin elevation, predicts long-term outcome in recreational marathon runners. Basic Res Cardiol. 2014 1; 109 1: 391 doi: 10.1007/s00395-013-0391-8. pmid:24253174
    OpenUrlCrossRefPubMed
  64. ↵
    1. Michaelides AP,
    2. Soulis D,
    3. Antoniades C,
    4. et al.
    Exercise duration as a determinant of vascular function and antioxidant balance in patients with coronary artery disease. Heart. 2011 5; 97 10: 832- 837. doi: 10.1136/hrt.2010.209080. pmid:21357374
    OpenUrlAbstract/FREE Full Text
  65. ↵
    1. Schnohr P,
    2. O'Keefe JH,
    3. Marott JL,
    4. Lange P,
    5. Jensen GB.
    Dose of jogging and long-term mortality: the Copenhagen City Heart Study. J Am Coll Cardiol. 2015 2 10; 65 5: 411- 419. doi: 10.1016/j.jacc.2014.11.023. pmid:25660917
    OpenUrlFREE Full Text
  66. ↵
    1. Lee DC,
    2. Pate RR,
    3. Lavie CJ,
    4. Sui X,
    5. Church TS,
    6. Blair SN.
    Leisure-time running reduces all-cause and cardiovascular mortality risk. J Am Coll Cardiol. 2014 8 5; 64 5: 472- 81. doi: 10.1016/j.jacc.2014.04.058. Erratum in: J Am Coll Cardiol. 2014 Oct 7;64(14):1537. pmid:25082581
    OpenUrlCrossRefPubMed
  67. ↵
    1. Abudiab M,
    2. Aijaz B,
    3. Konecny T,
    4. et al.
    Use of functional aerobic capacity based on stress testing to predict outcomes in normal, overweight, and obese patients. Mayo Clin Proc. 2013 12; 88 12: 1427- 1434. doi: 10.1016/j.mayocp.2013.10.013. pmid:24290116
    OpenUrlCrossRefPubMed
    1. Barnes JN,
    2. Joyner MJ.
    Physical activity and cardiovascular risk: 10 metabolic equivalents or bust. Mayo Clin Proc. 2013 12; 88 12: 1353- 1355. doi: 10.1016/j.mayocp.2013.10.015. pmid:24290107
    OpenUrlCrossRefPubMed
  69. ↵
    1. Kodama S,
    2. Saito K,
    3. Tanaka S,
    4. et al.
    Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women: a meta-analysis. JAMA. 2009 5 20; 301 19: 2024- 2035. doi: 10.1001/jama.2009.681. pmid:19454641
    OpenUrlCrossRefPubMed
  70. ↵
    1. Williams PT,
    2. Thompson PD.
    Increased cardiovascular disease mortality associated with excessive exercise in heart attack survivors. Mayo Clin Proc. 2014 9; 89 9: 1187- 1194. doi: 10.1016/j.mayocp.2014.05.006. pmid:25128072
    OpenUrlCrossRefPubMed
  71. ↵
    2008 Physical Activity Guidelines for Americans. U.S. Department of Health and Human Services. http://health.gov/paguidelines/pdf/paguide.pdf. Accessed July 14, 2016.
  72. ↵
    1. Lee DC,
    2. Lavie CJ,
    3. Vedanthan R.
    Optimal dose of running for longevity: is more better or worse? J Am Coll Cardiol. 2015 2 10; 65 5: 420- 422. doi: 10.1016/j.jacc.2014.11.022. pmid:25660918
    OpenUrlCrossRefPubMed
    1. Schnohr P,
    2. Marott JL,
    3. Lange P,
    4. Jensen GB.
    Longevity in male and female joggers: the Copenhagen City Heart Study. Am J Epidemiol. 2013 4 1; 177 7: 683- 689. doi: 10.1093/aje/kws301. pmid:23449779
    OpenUrlCrossRefPubMed
  74. ↵
    1. Wen CP,
    2. Wai JP,
    3. Tsai MK,
    4. et al.
    Minimum amount of physical activity for reduced mortality and extended life expectancy: a prospective cohort study. Lancet. 2011 10 1; 378 9798: 1244- 1253. doi: 10.1016/S0140-6736(11)60749-6. pmid:21846575
    OpenUrlCrossRefPubMed
  75. ↵
    1. Wen CP,
    2. Wai JP,
    3. Tsai MK,
    4. Chen CH.
    Minimal amount of exercise to prolong life: to walk, to run, or just mix it up? J Am Coll Cardiol. 2014 8 5; 64 5: 482- 484. doi: 10.1016/j.jacc.2014.05.026. pmid:25082582
    OpenUrlCrossRefPubMed
  76. ↵
    1. Chugh SS,
    2. Weiss JB.
    Sudden cardiac death in the older athlete. J Am Coll Cardiol. 2015 2 10; 65 5: 493- 502. doi: 10.1016/j.jacc.2014.10.064. pmid:25660928
    OpenUrlCrossRefPubMed
  77. ↵
    1. Biffi A,
    2. Pelliccia A,
    3. Verdile L,
    4. et al.
    Long-term clinical significance of frequent and complex ventricular tachyarrhythmias in trained athletes. J Am Coll Cardiol. 2002 8 7; 40 3: 446- 452. pmid:12142109
    OpenUrlFREE Full Text
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords